Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $141.10 | Total: $705.50 |
| 1 | 10 | $119.52 | Total: $1,195.20 |
| 1 | 25 | $101.26 | Total: $2,531.50 |
| 1 | 50 | $86.32 | Total: $4,316.00 |
| 1 | 100 | $74.70 | Total: $7,470.00 |
Overview
XMU-MP-2 is a potent and selective protease inhibitor with anticancer activity that inhibits the growth of oncogenic BRK-driven tumors in a mouse xenograft model.
Chemical Properties
| Molecular Formula | C32H33F3N8O2 |
| Molecular Weight | 618.65 |
| CAS Numbers | 2031152-10-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CN1C=2C(CN(C1)C3=CC(NC(=O)C4=CC(C(F)(F)F)=CC=C4)=CC=C3C)=CN=C(NC=5C=CC(=NC5)N6CCC(O)CC6)N2 |
Storage and Handling
0C Short Term, -20C Long Term
References
Jiang J,et al. Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors. Cancer Res. 2017 Jan 1;77[1] 175-186.